MedPath

AFFiRiS AG

AFFiRiS AG logo
🇦🇹Austria
Ownership
Holding
Established
2003-01-01
Employees
101
Market Cap
-
Website
http://www.affiris.com

Observational Follow-up Extension Study of AFF002 and AFF004A in Patients With Alzheimer's Disease

Terminated
Conditions
Alzheimer´s Disease
First Posted Date
2011-05-23
Last Posted Date
2013-12-11
Lead Sponsor
Affiris AG
Target Recruit Count
11
Registration Number
NCT01357629
Locations
🇦🇹

Studienzentrum der PROSENEX Ambulatoriumsbetriebs GmbH, Vienna, Austria

🇦🇹

Univ. Klinik für Psychiatire und Psychotherapie, Wien, Austria

Safety and Tolerability of AFFITOPE AD03

Phase 1
Completed
Conditions
Alzheimer's Disease
Interventions
Biological: AFFITOPE AD03
Biological: AFFITOPE AD03 + Alum
First Posted Date
2011-03-07
Last Posted Date
2011-12-20
Lead Sponsor
Affiris AG
Target Recruit Count
28
Registration Number
NCT01309763
Locations
🇦🇹

MUW Wien, Vienna, Austria

Safety, Immunogenicity and Dose Response of ATH03, a New Vaccine Against the Cholesterol Ester Transfer Protein (CETP)

Phase 1
Completed
Conditions
HDL
Drug Safety
Interventions
Biological: ATH03
First Posted Date
2011-01-27
Last Posted Date
2012-10-05
Lead Sponsor
Affiris AG
Target Recruit Count
36
Registration Number
NCT01284582
Locations
🇦🇹

Department for Clinical Pharmacology Medical University Vienna, Vienna, Austria

AD01 Follow up Extension Visit

Completed
Conditions
Alzheimer´s Disease
First Posted Date
2010-10-21
Last Posted Date
2011-01-26
Lead Sponsor
Affiris AG
Target Recruit Count
17
Registration Number
NCT01225809
Locations
🇦🇹

Univ. Klinik für Neurologie, Wien, Austria

Clinical- and Immunological Activity, Safety and Tolerability of Different Doses / Formulations of AFFITOPE AD02 in Early Alzheimer's Disease

Phase 2
Completed
Conditions
Alzheimer's Disease
First Posted Date
2010-05-06
Last Posted Date
2013-12-11
Lead Sponsor
Affiris AG
Target Recruit Count
335
Registration Number
NCT01117818
Locations
🇭🇷

Opća bolnica Varaždin, Klinika za Neurologiju, Varaždin, Croatia

🇦🇹

LNK Wagner-Jauregg, Dept. of geriatrics, Linz, Austria

🇦🇹

MUW, Klin.Abt.f. Biolog. Psychiatrie, Vienna, Austria

and more 28 locations

Safety/Tolerability, Immunological and Clinical Activity of a Boost Immunization With AFFITOPE AD02

Phase 1
Completed
Conditions
Alzheimer's Disease
Interventions
Biological: AFFITOPE AD02
First Posted Date
2010-03-26
Last Posted Date
2010-10-19
Lead Sponsor
Affiris AG
Target Recruit Count
20
Registration Number
NCT01093664
Locations
🇦🇹

Ordination Schmitz, Vienna, Austria

Long-term Safety and Tolerability of AFFITOPE AD01

Completed
Conditions
Alzheimer's Disease
First Posted Date
2008-07-08
Last Posted Date
2010-05-27
Lead Sponsor
Affiris AG
Target Recruit Count
22
Registration Number
NCT00711139
Locations
🇦🇹

Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria

Long-term Safety and Tolerability of AFFITOPE AD02

Completed
Conditions
Alzheimer's Disease
First Posted Date
2008-07-08
Last Posted Date
2010-05-27
Lead Sponsor
Affiris AG
Target Recruit Count
23
Registration Number
NCT00711321
Locations
🇦🇹

Ordination Schmitz, Vienna, Austria

Tolerability and Safety of Subcutaneous Administration of AFFITOPE AD02 in Mild to Moderate Alzheimer's Disease

Phase 1
Completed
Conditions
Alzheimer's Disease
Interventions
Biological: AFFITOPE AD02
First Posted Date
2008-03-12
Last Posted Date
2010-10-19
Lead Sponsor
Affiris AG
Target Recruit Count
24
Registration Number
NCT00633841
Locations
🇦🇹

Ordination Univ. Doz. Dr. Margot Schmitz, Vienna, Austria

Tolerability and Safety of Subcutaneous Administration of Affitope AD01 in Mild to Moderate Alzheimer's Disease

Phase 1
Completed
Conditions
Alzheimer's Disease
Interventions
Biological: AFFITOPE AD01
Biological: AFFITOPE AD01 adjuvanted
First Posted Date
2007-07-03
Last Posted Date
2010-10-19
Lead Sponsor
Affiris AG
Target Recruit Count
24
Registration Number
NCT00495417
Locations
🇦🇹

Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria

© Copyright 2025. All Rights Reserved by MedPath